Home
Reels
Groups
Pages
See More
Groups Pages My Blogs My Offers My Jobs My Courses Events Blogs Offers Jobs Courses Forums Movies Games
Sign In Sign Up
Day Mode
TUDRIQEV Approval for Advanced Melanoma: Regulatory Progress, Mechanism, and Clinical Outlook
Replimune has reached an important milestone in oncology with the FDA’s accelerated approval of tudriqev (vusolimogene oderparepvec-wtpg), previously identified as RP1, in combination with Bristol Myers Squibb’s OPDIVO (nivolumab). Granted on August 6, 2026, the approval applies to adults with unresectable, advanced cutaneous melanoma that has progressed after treatment with an...
0 Comments ·0 Shares ·193 Views ·0 Reviews
Please log in to like, share and comment!
Villagge https://villagge.com